Business Context and Reporting Period
Orthofix Medical Inc. (OFIX) filed a Form 8-K on November 7, 2024, reporting the entry into a new material definitive agreement and the termination of a prior financing arrangement. The company is incorporated in Delaware and operates in the medical device sector.
Key Financial Metrics and Debt Structure
The filing details a new $275 million secured credit agreement with Oxford Finance LLC and other lenders. The capital structure includes:
- Initial Term Loan: $160 million senior secured term loan.
- Term B Loan: $65 million senior secured delayed draw term loan facility (available Jan 1, 2025 – June 30, 2026).
- Term C Loan: Up to $50 million additional draw capacity at lender discretion (available through Jan 1, 2029).
- Interest Rate: Greater of 8.75% or 5.75% plus one-month term SOFR.
- Fees: 1.5% facility fee on funded tranches; 0.5% annual unused line fee on Term B.
- Maturity: November 2029, with an interest-only period ending December 2028.
The filing does not provide specific values for revenue, profit, cash flow, or operating margins as this is a current report regarding debt restructuring rather than a periodic financial statement.
Material Changes Versus Prior Period
On the effective date of the new agreement, Orthofix repaid all outstanding amounts and terminated its previous Financing Agreement dated November 6, 2023, with Blue Torch Finance, LLC. This action replaces the prior debt facility with the new Oxford Finance-led structure.
Guidance, Covenants, and Risks
The new credit agreement imposes specific financial and operational covenants:
- Leverage Ratio: The company must maintain a maximum total debt-to-EBITDA leverage ratio of no greater than 4.0x. Draws on the Term B Loan are contingent on maintaining a pro-forma ratio below 4.0x.
- Liquidity Requirements: The company must possess at least $45 million of unrestricted cash at funding and maintain a minimum of $15 million of unrestricted cash in U.S.-based accounts thereafter.
- Restrictions: Customary limitations on incurring additional debt, granting liens, making acquisitions, paying dividends, and entering affiliate transactions.
- Collateral: The facilities are secured by a first-priority lien on substantially all company assets, including U.S. intellectual property.
Management commentary is limited to the terms of the agreement; no forward-looking revenue or earnings guidance is provided in this filing.
Key Facts for Investor Verification
- Verify the company's current unrestricted cash balance to ensure compliance with the $45 million funding requirement and $15 million maintenance covenant.
- Confirm the pro-forma total debt-to-EBITDA ratio to assess eligibility for drawing the $65 million Term B Loan.
- Review the full text of the Loan and Security Agreement (Exhibit 10.1) for specific definitions of EBITDA addbacks and carveouts.
- Monitor the interest rate environment, as the cost of debt is tied to the one-month term SOFR plus a significant margin.